NCT06787131View on ClinicalTrials.gov

Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

July 4, 2025

Study Completion Date

July 4, 2025

Conditions
Healthy
Interventions
DRUG

ZE50-0134 or placebo

The patients will receive ZE50-0134 or placebo.

DRUG

Rabeprazole 20 mg

Rabeprazole 20 mg once daily (QD) on Day 1 and Day 2.

DRUG

Itraconazole (200 mg)

Itraconazole 200 mg twice per day.

Trial Locations (1)

2031

Scientia Clinical Research, Sydney

Sponsors
All Listed Sponsors
lead

Eilean Therapeutics

INDUSTRY

NCT06787131 - Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers | Biotech Hunter | Biotech Hunter